We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Re-Engineering Red Blood Cells To Deliver Vaccines
News

Re-Engineering Red Blood Cells To Deliver Vaccines

Re-Engineering Red Blood Cells To Deliver Vaccines
News

Re-Engineering Red Blood Cells To Deliver Vaccines

Credit: ANIRUDH/ Unsplash
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Re-Engineering Red Blood Cells To Deliver Vaccines"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Physicists, chemists and immunologists at McMaster University have teamed up to modify red blood cells to transport viral agents which can safely trigger the immune system to protect the body against SARS-CoV-2, creating a promising new vehicle for vaccine delivery.


Developing new strategies and vaccine technologies is critical for controlling the pandemic and preparing for future outbreaks as the coronavirus continues to evolve and mutate, say the researchers.


The new method, described in the journal PLOS ONE is an entirely unique approach to vaccination. Red blood-cell membranes are embedded with SARS-CoV-2 spike proteins, which then form virus-like particles.


“We take red blood cells and remove everything from the inside. We then attach spike proteins to their outside to mimic a coronavirus,” explains graduate student Isabella Passos-Gastaldo, a lead author on the paper.


The particles, shown to activate the immune system and produce antibodies in mice, are completely harmless.


“Current vaccine delivery methods often cause drastic immune system reactions and have short-lived responses,” says Maikel Rheinstadter, a senior supervisor on the paper and a professor in the Department of Physics & Astronomy at McMaster.


“Some of the vaccines that have been developed have shown side effects. This delivery platform opens new possibilities for vaccines and therapeutics.”


The researchers found cells can be loaded with a large dose of viral proteins, yet likely produce few side effects, making the new method more tolerable and effective than other vaccine options.


“We have developed a method where we can trigger an immune response without the use of genetic material and yet we are able to synthesize these particles in a very short amount of time,” says Sebastian Himbert, lead author on the study and a recent graduate student in the Department of Physics & Astronomy at McMaster.


The technology can be quickly adapted to develop vaccines for variants or new viruses that may emerge in future.


“This is the kind of creative, interdisciplinary research that McMaster is known for. It was exhilarating working with physicists, structural biologists and immunologists to design a radically different vaccine platform,” says Dawn Bowdish, Professor of Medicine at McMaster and Canada Research Chair in Aging & Immunity and co-author of the paper.


The researchers first reported this technique in 2020, when they modified red blood cells to deliver drugs throughout the body, which could then target infections or treat catastrophic diseases such as cancer or Alzheimer’s.


“This platform makes our own blood cells smart in many different ways,” explains Rheinstadter. In this case it’s a vaccine.”


“We are using our own cells much like nano robots inside of our bodies and whenever they see a disease, they can fight it.”


Reference: Himbert S, Gastaldo IP, Ahmed R, et al. Erythro-VLPs: Anchoring SARS-CoV-2 spike proteins in erythrocyte liposomes. PLoS ONE. 2022;17(3):e0263671. doi: 10.1371/journal.pone.0263671

  

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.


Advertisement